Avalon GloboCare Corp. (NASDAQ:ALBT) Sees Large Increase in Short Interest

Avalon GloboCare Corp. (NASDAQ:ALBT) was the recipient of a significant increase in short interest during the month of December. As of December 31st, there was short interest totaling 111,024 shares, an increase of 37.1% from the December 15th total of 80,987 shares. Currently, 2.9% of the shares of the stock are short sold. Based on an average daily volume of 145,299 shares, the days-to-cover ratio is currently 0.8 days. Based on an average daily volume of 145,299 shares, the days-to-cover ratio is currently 0.8 days. Currently, 2.9% of the shares of the stock are short sold.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Avalon GloboCare in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Sell”.

Avalon GloboCare Trading Up 2.6%

Avalon GloboCare stock opened at $1.17 on Monday. The stock has a market cap of $4.97 million, a PE ratio of -0.33 and a beta of -0.09. Avalon GloboCare has a 52 week low of $0.88 and a 52 week high of $11.66. The stock has a 50-day moving average price of $1.37 and a 200 day moving average price of $1.99.

Avalon GloboCare (NASDAQ:ALBT) last announced its earnings results on Friday, November 14th. The company reported ($0.06) earnings per share (EPS) for the quarter. The company had revenue of $0.35 million for the quarter.

Avalon GloboCare Company Profile

Avalon GloboCare is a clinical-stage biopharmaceutical company specializing in the research, development and commercialization of next-generation cell-based therapies and exosome-based diagnostics. The company’s pipeline focuses on allogeneic chimeric antigen receptor T-cell (CAR-T) and CAR-natural killer (CAR-NK) programs targeting hematological malignancies and solid tumors, alongside proprietary exosome platforms for noninvasive cancer detection.

Through its R&D facilities in both the United States and China, Avalon GloboCare integrates cell engineering, genetic modification and biomarker discovery to advance therapeutic and diagnostic candidates from preclinical research into human studies.